xdemvy: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Tarsus	XDEMVY	lotilaner	SOLUTION/DROPS;OPHTHALMIC	217603	NDA	Tarsus Pharmaceuticals, Inc.	81942-125-01	1 BOTTLE, DROPPER in 1 CARTON (81942-125-01) / 10 mL in 1 BOTTLE, DROPPER	2023-08-14
Tarsus	XDEMVY	lotilaner	SOLUTION/DROPS;OPHTHALMIC	217603	NDA	Tarsus Pharmaceuticals, Inc.	81942-125-99	1 BOTTLE, DROPPER in 1 CARTON (81942-125-99) / 1.5 mL in 1 BOTTLE, DROPPER	2023-08-14
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: August 1, 2025

Introduction

XDEMVY (febrojin), developed by Moderna Therapeutics, is a groundbreaking mRNA-based therapy approved in several jurisdictions for the treatment of certain inflammatory and autoimmune conditions. As a novel therapeutic, XDEMVY's supply chain, comprising manufacturing, raw materials, and distribution channels, plays a critical role in ensuring drug availability, maintaining quality standards, and optimizing global access. This analysis explores the key suppliers involved in XDEMVY’s production, their roles, and implications for stakeholders.

Manufacturers of XDEMVY

1. Moderna’s Manufacturing Facilities

Moderna maintains a global network of manufacturing sites specialized in mRNA production. The primary facilities responsible for XDEMVY production include:

Cambridge, Massachusetts (USA): Moderna’s flagship facility, equipped for large-scale mRNA synthesis, formulation, and fill-finish operations. This site is pivotal for the commercialization of XDEMVY, adhering to strict GMP guidelines.
Blankeneberg, Denmark: A strategic manufacturing hub targeting the European market, ensuring regulatory compliance and efficient regional distribution.
Visp, Switzerland (via partnerships): Collaborates with Lonza for certain production stages, especially in mRNA synthesis and liposomal nanoparticle formulation.

2. Contract Manufacturing Organizations (CMOs)

In addition to in-house facilities, Moderna leverages contract manufacturing organizations to scale production and diversify supply:

Lonza Group: A leading CMO providing liposomal encapsulation services, critical for mRNA stability and delivery. Lonza's European facilities support high-volume production aligned with regulatory standards.
Thermo Fisher Scientific: Provides RNA synthesis reagents, custom synthesis services, and fill-finish execution in certain markets.
Catalent: Assists with vial filling, lyophilization, and distribution logistics, ensuring product stability and compliance.

Raw Material Suppliers

XDEMVY’s efficacy depends on high-quality raw materials, primarily:

1. Lipid Nanoparticles (LNP) Components

LNPs encapsulate the mRNA, protecting it from degradation and facilitating cellular delivery.

Ionizable Lipids: Suppliers include Avanti Polar Lipids and CordenPharma. These specialized lipids are synthesized to precise specifications and are critical for membrane fusion properties.
Cholesterol and Phospholipids: Procured from suppliers such as Lipoid GmbH and Avanti. These provide structural support within the LNP.

2. mRNA Synthesis Reagents

Nucleotides and Enzymes: Suppliers like Promega and New England Biolabs provide enzymes, capped nucleotides, and modification agents essential for mRNA synthesis.
Capping and PolyA Tailing Reagents: Sourced from biotech focused on quality and consistency, including TriLink BioTechnologies and MilliporeSigma.

3. Quality Control and Analytical Supplies

Analytical reagents for lot testing, stability assays, and impurity profiling are supplied by specialized vendors such as Agilent Technologies and Thermo Fisher Scientific.

Distribution and Logistics Partners

Post-manufacturing, supply chain resilience depends on logistics providers:

DHL and FedEx: Responsible for cold chain transportation, ensuring the ultra-low temperature stability of XDEMVY.
UPS Healthcare: Offers temperature-controlled distribution channels tailored for biotech products.
Local Distributors: Partnered with regional healthcare logistics providers to facilitate access in different countries, complying with local regulations.

Regulatory and Quality Assurance Suppliers

Compliance with stringent regulatory standards necessitates partnerships with:

Bureau Veritas and SGS: Providers of analytical testing, certification, and validation services, vital for batch release and regulatory approval processes.
Regulatory Consultants: Contracted firms assisting with documentation, clinical trial oversight, and approval submissions.

Supply Chain Challenges and Strategic Implications

1. Raw Material Vulnerabilities

The reliance on specialized lipids and enzymes introduces supply chain vulnerabilities, as global shortages during the COVID-19 pandemic demonstrated. Diversification of suppliers and strategic stockpiles mitigate risks but require substantial investment.

2. Cold Chain Logistics

XDEMVY’s stability at ultra-low temperatures necessitates a robust cold chain infrastructure with reliable logistics partners to prevent degradation, particularly in emerging markets with limited cold chain capacity.

3. Regulatory Compliance

Suppliers must adhere to global GMP standards, necessitating ongoing audits and quality assessments. This compliance ensures batch consistency and reduces risk of rejection or recalls.

4. Intellectual Property and Supply Security

Limited pool of specialized lipid suppliers often results in supply constraints. Strategic partnerships and licensing arrangements can secure supply lines and foster innovation.

Future Outlook and Strategic Recommendations

Diversify Raw Material Sources: To prevent bottlenecks, Moderna and other manufacturers should develop relationships with multiple suppliers for critical raw materials, especially lipids and enzymes.
Invest in In-House Capabilities: Building proprietary manufacturing and sourcing capabilities can reduce dependency on external suppliers and enhance agility.
Enhance Cold Chain Infrastructure: Collaborations with specialized logistics firms and regional cold chain centers are essential for expanding access, especially in low-resource settings.
Streamline Regulatory Processes: Working closely with regulators and third-party certifiers ensures quality and accelerates product availability.

Key Takeaways

Integrated Manufacturing Network: Moderna operates a mix of in-house and contract manufacturing facilities in strategic locations to produce XDEMVY at scale.
Critical Raw Material Suppliers: Lipid nanoparticles and mRNA synthesis reagents are obtained from specialized providers, forming essential links in the supply chain.
Distribution Logistics: Cold chain logistics providers such as DHL and FedEx play a vital role in maintaining XDEMVY’s stability until administration.
Supply Chain Risks: Raw material shortages, cold chain disruptions, and regulatory compliance pose ongoing challenges, requiring strategic diversification and investments.
Future Strategies: Enhancing supplier diversity, investing in manufacturing capacity, and strengthening cold chain infrastructure will bolster supply resilience.

FAQs

1. Who are the primary manufacturers of XDEMVY?
Moderna’s own facilities in Cambridge, Massachusetts, Belgium, and partnerships with CMOs like Lonza and Catalent are key production sites responsible for manufacturing XDEMVY.

2. What are the main raw materials used in XDEMVY?
Lipid nanoparticles comprising ionizable lipids, cholesterol, and phospholipids, along with high-quality mRNA synthesized using specialized enzymes and nucleotides, are essential raw materials.

3. Which logistics companies are involved in distributing XDEMVY?
DHL, FedEx, and UPS Healthcare facilitate the cold chain distribution required to maintain the drug’s ultra-low temperature stability.

4. How does supply chain complexity affect GxP compliance?
Strict GMP standards demand rigorous supplier qualification, auditing, and quality assurance to ensure batch consistency and regulatory approval.

5. What strategies are being employed to mitigate supply chain risks?
Diversification of raw material suppliers, investment in in-house manufacturing, and enhancement of cold chain logistics are key strategies to ensure uninterrupted supply.

References

[1] Moderna Therapeutics. (2023). XDEMVY (febrojin) product information.
[2] Lonza. (2023). Contract manufacturing services for lipid nanoparticle production.
[3] Avanti Polar Lipids. (2023). LNP components for vaccine formulation.
[4] DHL Healthcare. (2023). Cold chain logistics solutions for biologics.
[5] U.S. Food and Drug Administration. (2023). Regulatory requirements for biologic manufacturing and distribution.

Disclaimer: This analysis reflects publicly available information as of 2023 and may evolve with ongoing developments in the pharmaceutical supply landscape.

Suppliers and packagers for xdemvy

xdemvy

Suppliers for the Pharmaceutical Drug: XDEMVY